

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/859,604	05/17/2001	Jack R. Wands	21486-032 CIP	5006
30623	7590 09/24/200	:		
	VIN, COHN, FERR	EXAMINER		
AND POPEO, P.C. ONE FINANCIAL CENTER			CANELLA, KAREN A	
BOSTON, M	A 02111		ART UNIT	PAPER NUMBER
			1642	11
			DATE MAILED: 09/24/2002	ŧŧ

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/859,604

Applicant(s)

Wands et al

Examiner

Karen Canella

Art Unit 1642



The MAILING DATE of this communication app	ears on the cover sheet with the correspondence address				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SE THE MAILING DATE OF THIS COMMUNICATION.					
 Extensions of time may be available under the provisions of 37 CFR 1.136 (a). mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within If NO period for reply is specified above, the maximum statutory period will app. Failure to reply within the set or extended period for reply will, by statute, caus. Any reply received by the Office later than three months after the mailing date earned patent term adjustment. See 37 CFR 1.704(b). 	ly and will expire SIX (6) MONTHS from the mailing date of this communication. e the application to become ABANDONED (35 U.S.C. § 133).				
Status					
1) Responsive to communication(s) filed on	•				
	action is non-final.				
closed in accordance with the practice under Ex	e except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.				
Disposition of Claims					
4) 💢 Claim(s) <u>1-46</u>	is/are pending in the application.				
4a) Of the above, claim(s)	is/are withdrawn from consideration.				
5) Claim(s)	is/are allowed.				
6) Claim(s)	is/are rejected.				
7) Claim(s)	is/are objected to.				
8) 💢 Claims <u>1-46</u>	are subject to restriction and/or election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/a	re a) \square accepted or b) \square objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)□ All b)□ Some* c)□ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No.					
 Copies of the certified copies of the priority application from the International Bu *See the attached detailed Office action for a list of 					
14) Acknowledgement is made of a claim for domes	tic priority under 35 U.S.C. § 119(e).				
a) The translation of the foreign language provisional application has been received.					
15) Acknowledgement is made of a claim for domes	tic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:					

Application/Control Number: 09/859,604

Art Unit: 1642

* * *

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-12, drawn to a method of confering an immune response comprising administering an antibody and a method of inhibiting tumor growth conprising administering an antibody conjugated to a cytotoxic agent, classified in class 424, subclasses 130.1 and 178.1.
 - II. Claims 13-24, drawn to a method of inducing a HAAH specific immune response comrpising administering HAAH polypeptide, classified in class 424, subclass 94.1.
 - III. Claims 25-30, drawn to a method for diagnosing neoplasms comprising contacting a tissue with a labeled antibody, classified in class 435, subclass 7.1.
 - IV. Claims 31-34, 45 and 46, drawn to frgments of HAAH, classified in class 530, subclass 300.
 - V. Claims 35-44, drawn to antibodies or fragments thereof, kits comprising said antibodies or fragments, and hybridoma cell lines, classified in class 530, subclass 387.1 and class 435, subclass 326.
- 2. The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups IV and V are structurally and functionally different products which are made by different methods and have different uses. The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

The methods of Groups I, II and III differ in the method objectives, method steps and parameters and in the reagents used.

Application/Control Number: 09/859,604 Page 3

Art Unit: 1642

Inventions IV and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the HAAH fragment of Invention IV can be used in a process to make the antibody of Invention V.

Inventions V and III are related as product and process of use. Inventions V and I are also related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Invention V can be used in either the method of Group I or III, or in a process of raising an anti-idiotypic antibody.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because the searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Page 4

Application/Control Number: 09/859,604

Art Unit: 1642

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Marin A. Ganilla. Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

September 23, 2002